+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in lipid profile over 24-months among adults on first-line highly active Antiretroviral therapy in the home-based AIDS care program in rural Uganda



Changes in lipid profile over 24-months among adults on first-line highly active Antiretroviral therapy in the home-based AIDS care program in rural Uganda



JAIDS Journal of Acquired Immune Deficiency Syndromes 47(3): 304-311



Background: Use of highly active antiretroviral therapy (HAART) has been linked to dyslipidemia and increased risk of cardiovascular disease (CVD) in HIV-infected patients in industrialized countries. The effects of HAART on lipid metabolism among sub-Saharan Africans, for whom access to antiretroviral therapy is expanding, remain largely unknown.Methods: From July 2003 to May 2004, 987 antiretroviral-naive patients with symptomatic HIV disease or a CD4 count < 250 cells/mm(3) were started on HAART in the Home-Based AIDS Care (HBAC) Program in Tororo, Uganda. The HBAC Program provided weekly drug delivery and field-based clinical monitoring. Nonfasting repository sera from a subset of 374 patients were analyzed for levels of total cholesterol (TC), direct low-density lipoprotein cholesterol (LDL-c), direct high-density lipoprotein cholesterol (HDL-c), and triglycerides (TG) at baseline (before HAART) and after 12 and 24 months of HAART using Randox enzymatic kits (Crumlin, United Kingdom).Results: The 374 patients evaluated (49% women, mean age = 39 years, CD4 count = 124 cells/mm(3), body mass index = 19.7 kg/m(2)) received initial HAART composed of stavudine, lamivudine, and either nevirapine (365 patients [98%]) or efavirenz (9 patients [2%]). During 24 months, 99 (26%) patients had single drug substitutions from stavudine to zidovudine and 27 (7%) had single drug substitutions from nevirapine to efavirenz. At baseline, the mean serum lipid concentrations were 120 mg/dL for TC, 53 mg/dL for LDL-c, 29 mg/dL for HDL-c, and 123 mg/dL for TG; values were generally comparable for men and women. During 24 months of treatment, TC increased by a mean of 31 mg/dL, LDL-c by a mean of 26 mg/dL, and HDL-c by a mean of 19 mg/dL, whereas the TC/HDL-c ratio decreased from a mean of 4.6 to 3.4 (all changes, P < 0.001). TG levels initially decreased and then returned to baseline levels by 24 months. At baseline and 24 months, respectively, TC was >= 200 mg/dL for 2% and 10% of patients, LDL-c was ! 130 mg/dL for 1% and 6%, HDL-c was < 40 mg/dL for 88% and 41%, and TG were >= 150 mg/dL for 23% and 20%.Conclusions: Rural Ugandans with advanced HIV disease initiating nevirapine- or efavirenz-based HAART experienced infrequent elevations in TC, LDL-c, and TG at baseline and after 24 months of therapy. Increases in HDL-c levels were substantial and proportionally greater than increases in TC or LDL-c levels. The risk of CVD and how it is affected by lipid changes in this rural African population are unknown. However, the changes we observed after 24 months of HAART seem unlikely to increase the risk of CVD.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 020704530

Download citation: RISBibTeXText

PMID: 18398971


Related references

Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based Aids Care Program in Rural Uganda. Jaids Journal of Acquired Immune Deficiency Syndromes 47(3): 304-311, 2008

Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. Journal of Acquired Immune Deficiency Syndromes 44(4): 456-462, 2007

Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368(9547): 1587-1594, 2006

Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. Aids Care 19(5): 626-636, 2007

Hematologic changes associated with Zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda. Journal of the International Association of Physicians in Aids Care 8(2): 128-138, 2009

HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda. Aids 21 Suppl 6: S21-S29, 2007

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. American Journal of Epidemiology 165(10): 1143-1153, 2007

Revelations of HIV-infected patients treated with highly active antiretroviral therapy (HAART) in rural Uganda. Aids Care 26(1): 75-78, 2014

The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. Aids Patient Care and Stds 16(2): 75-81, 2002

High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clinical Infectious Diseases 49(1): 155-159, 2009

Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. Bmc Infectious Diseases 14: 496, 2014

Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. International Journal of Women's Health 2: 45-52, 2010

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antiviral Therapy 14(2): 293-297, 2009

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Applied Health Economics and Health Policy 7(4): 229-243, 2010

Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study. Pan African Medical Journal 12: 21, 2012